Pillartree Limited, a new subsidiary of Amgen, has struck a deal to acquire Horizon Therapeutics, which markets Uplizna (inebilizumab-cdon) for neuromyelitis optica spectrum disorder (NMOSD). Last month, Horizon announced that it was in preliminary discussions about a potential sale to three pharmaceutical companies — Amgen,…
Drug updates
Merck KGaA will continue to advance CRD1 for the treatment of neuromyelitis optica spectrum disorder (NMOSD) and generalized myasthenia gravis (gMG), after the company acquired the therapy’s original developer, Chord Therapeutics. The investigational therapy is an oral cladribine product that works by reducing the number of immune cells, namely…
Horizon Therapeutics is growing its rare disease portfolio by acquiring the biotechnology company Viela Bio, including the approved medicine Uplizna for treating neuromyelitis optica spectrum disorder (NMOSD). “This acquisition represents a significant step forward in advancing our strategy — to expand our pipeline,” Tim Walbert, chairman,…
Recent Posts
- Treatment linked to fewer NMOSD relapses, less steroid use in study
- Navigating NMOSD at the intersection of culture and family
- Review shows approved treatment sharply cuts relapse risk in NMOSD
- Choosing courage and connection after the trauma of NMOSD
- NMOSD patients report lower sleep quality, study shows